Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.
Rochelle E. Curtis(National Institutes of Health), H. Joachim Deeg(Fred Hutch Cancer Center), Gèrard Socié(Hôpital Saint-Louis), Keith M. Sullivan(Duke Medical Center), Lois B. Travis(Indiana University – Purdue University Indianapolis), Peter M. Banks(National Cancer Institute), Daniel J. Weisdorf(University of Minnesota), Robert Peter Gale(Imperial College London), Elaine S. Jaffe(National Cancer Institute), Mary M. Horowitz(Medical College of Wisconsin), Philip A. Rowlings(Medical College of Wisconsin), Joseph F. Fraumeni(National Institutes of Health), George E. Sale, H. Kolb(National Cancer Institute), Douglas W. Kingma(National Cancer Institute), Kathleen A. Sobocinski(Medical College of Wisconsin), Donna A. Shriner(National Cancer Institute), Robert P. Witherspoon(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Robert N. Hoover(Tulane University)
PubMed
October 1, 1999
Cited by 651
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k